Unknown

Dataset Information

0

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.


ABSTRACT: OBJECTIVE:To investigate the origin of the HIV-1 viremia induced by the latency-reversing agent romidepsin. DESIGN:Six individuals on suppressive antiretroviral therapy received romidepsin administered intravenously once weekly for 3 consecutive weeks. CD4 T cells were obtained at baseline, following the second and third romidepsin infusion, and 10 weeks after the final romidepsin treatment. Plasma samples were collected 24 and 72 h after romidepsin infusions. METHODS:Single-genome sequencing of the env and p24-RT region was used to genetically characterize the virus from proviral DNA, the transcribed cell-associated RNA and the plasma RNA pool. RESULTS:In three of six participants with available plasma samples we identified plasma HIV-1 RNA sequences that were identical to DNA and/or cell-associated RNA sequences from peripheral blood CD4 T cells. In two participants, plasma RNA sequences contained expansions of identical sequences, corresponding to 62 and 100% of the total sequences, respectively. Plasma HIV-1 RNA had very low amounts of defective viruses compared to cell-associated RNA (odds ratio 20.85, P?

SUBMITTER: Winckelmann A 

PROVIDER: S-EPMC5345886 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.

Winckelmann Anni A   Barton Kirston K   Hiener Bonnie B   Schlub Timothy E TE   Shao Wei W   Rasmussen Thomas A TA   Østergaard Lars L   Søgaard Ole S OS   Tolstrup Martin M   Palmer Sarah S  

AIDS (London, England) 20170301 6


<h4>Objective</h4>To investigate the origin of the HIV-1 viremia induced by the latency-reversing agent romidepsin.<h4>Design</h4>Six individuals on suppressive antiretroviral therapy received romidepsin administered intravenously once weekly for 3 consecutive weeks. CD4 T cells were obtained at baseline, following the second and third romidepsin infusion, and 10 weeks after the final romidepsin treatment. Plasma samples were collected 24 and 72 h after romidepsin infusions.<h4>Methods</h4>Singl  ...[more]

Similar Datasets

| S-EPMC3126162 | biostudies-literature
| S-EPMC178335 | biostudies-other
| S-EPMC1219338 | biostudies-other
| S-EPMC2263042 | biostudies-literature
| S-EPMC3294249 | biostudies-literature
| S-EPMC3125170 | biostudies-literature
| S-EPMC5973480 | biostudies-literature
| S-EPMC6898779 | biostudies-literature
| S-EPMC7108420 | biostudies-literature
| S-EPMC6535334 | biostudies-literature